Anlotinib
CAS No. 1058156-90-3
Anlotinib( AL-3818 )
Catalog No. M10263 CAS No. 1058156-90-3
Anlotinib (AL-3818) is a novel multi-target tyrosine kinase that primarily inhibit VEGFR2/3, FGFR1-4, PDGFR α/β, c-Kit, and Ret.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
Size | Price / USD | Stock | Quantity |
100MG | Get Quote | In Stock |
|
200MG | Get Quote | In Stock |
|
500MG | Get Quote | In Stock |
|
1G | Get Quote | In Stock |
|
Biological Information
-
Product NameAnlotinib
-
NoteResearch use only, not for human use.
-
Brief DescriptionAnlotinib (AL-3818) is a novel multi-target tyrosine kinase that primarily inhibit VEGFR2/3, FGFR1-4, PDGFR α/β, c-Kit, and Ret.
-
DescriptionAnlotinib (AL-3818) is a novel multi-target tyrosine kinase that primarily inhibit VEGFR2/3, FGFR1-4, PDGFR α/β, c-Kit, and Ret; shows antitumor activity against tumor cells carrying mutations in PDGFR α, c-Kit, Met, and epidermal growth factor receptor (EGFR).Colon Cancer Phase 2 Clinical.
-
In Vitro——
-
In Vivo——
-
SynonymsAL-3818
-
PathwayAngiogenesis
-
TargetEGFR
-
RecptorEGFR
-
Research AreaCancer
-
IndicationColon Cancer
Chemical Information
-
CAS Number1058156-90-3
-
Formula Weight407.4375
-
Molecular FormulaC23H22FN3O3
-
Purity>98% (HPLC)
-
SolubilityDMSO: ≥ 44 mg/mL
-
SMILESCC1=CC2=C(N1)C=CC(=C2F)OC3=C4C=C(C(=CC4=NC=C3)OCC5(CC5)N)OC
-
Chemical NameCyclopropanamine, 1-[[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-quinolinyl]oxy]methyl]-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Sun Y, et al. J Hematol Oncol. 2016 Oct 4;9(1):105.
molnova catalog
related products
-
PD153035 hydrochlori...
PD153035 hydrochloride (ZM 252868; AG 1517) is a potent and specific inhibitor of EGFR with Ki and IC50 of 5.2 pM and 29 pM; little effect against PGDFR, FGFR, CSF-1, InsR and Src.
-
R162
R162 is an effective glutamate dehydrogenase 1 (GDH1) inhibitor.
-
(Rac)-JBJ-04-125-02
JBJ-04-125-02 is effective as a single agent in both in vitro and in vivo models of EGFR-mutant lung cancer.